Hypergendered Logic Source
Hypergendered Logic — Page 284
437. Medication classes For every named Archwomanhood and Archmanhood hormone, the fictional pharmacopoeia contains medications capable of increasing hormone amount, decreasing hormone amount, or suppressing/stopping effective hormone exposure. For every corresponding receptor system, medications can increase effective sensitivity, decrease effective sensitivity, or make the receptor system completely insensitive. Hormone interventions: AmountUp_i, AmountDown_i, AmountStop_i. Receptor interventions: Sensitize_i, Desensitize_i, Insensitize_i. Because amount controls interval and sensitivity controls jump magnitude, these medication classes provide two conceptually independent clinical levers: pacing and jump-size control. Combination therapy can intentionally pair an amount intervention with the opposite receptor intervention—for example, frequent small jumps or infrequent large jumps—without treating those as contradictory prescriptions. 438. Medication does not equal stage reversal A hormone-lowering drug, hormone stopper, receptor desensitizer, or receptor blocker alters future hormone-mediated progression. It does not logically subtract already attained Archstage. A patient at a high address can be pharmacologically stabilized there. If a future medicine is intended to cause actual Archstage regression, the theory requires a distinct regression operator and its own biological law. AmountDown/Stop or Desensitize/Insensitize => reduced/stopped future drive, not automatic coordinate decrease. 439. Archdevelopmental Adaptation Load To formalize the user-supplied concern that racing through Archwomanhood/Archmanhood every second, hour, or day may be overwhelming, uncomfortable, or later regretted without implying that the underlying Archstage quality became worse, define Archdevelopmental Adaptation Load (AAL). AAL is a separate clinical variable describing the transient biological/psychological burden of integrating stage change relative to the bearer's adaptation capacity. AAL = F(jump magnitudes, jump intervals, number of simultaneously active axes, ordinary maturity, history, context, individual adaptation capacity). No exact formula is currently canonized. High AAL is compatible with increasing HGL whole-form quality. Therefore discomfort, fatigue, disequilibrium, distress, or regret risk—if a causal law produces them—must not be misclassified as proof that the new Archstage is a Flaw or lower whole-form quality. 440. Cross-axis synchronization and asynchronous advancement Because five endocrine controllers can be tuned independently, Archstage development is a multiaxial control problem. One clinically important question is whether a particular individual benefits from synchronized changes or from deliberate staggering. Rapid Substage^3 advancement while Stage and Hyperstage are static may have different adaptation consequences from a simultaneous large Stage and Hyperstage jump. The logic does not automatically label asynchrony harmful. Instead, asynchronous interaction is a major CI/research domain. Exact effects require causal models. This is precisely the kind of problem that makes Archgynocology and Archandrocology more than simple hormone-prescription services. 441. Ordinary womanhood/manhood interaction is not collapsed into Archstage Ordinary womanhood and manhood remain distinct developmental systems. However, the new medical specialties explicitly study how Archstage hormone balances, receptor sensitivities, jump magnitudes, intervals, plateaus, and histories interact with ordinary female/male development and wellbeing. The
Source Canon: Verbatim mathematical and modal logic. Interactive navigation and operator lookups available at /#hgl-part:284.